Summary

The final results of the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition [CHAMPION] PCI [NCT00305162] and CHAMPION PLATFORM [NCT00385138] trials showed no clinical benefit with cangrelor for the primary composite outcome of death, myocardial infarction, and ischemic-driven revascularization in patients who were undergoing percutaneous coronary intervention.